文献速递乳房整形与再造

Artia™组织基质辅助假体乳房再造的前瞻性研究

Implant-based breast reconstruction with Artia™ tissue matrix.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2019-05-22

中位随访276天后总体并发症率为10.8%,包括血清肿需抽吸6侧(7.2%)、血肿1侧(1.2%)和假体丧失2侧(2.4%),无伤口裂开或红斑/红乳综合征。作者认为Artia™辅助假体乳房再造早期并发症率低且可接受,与成熟ADM经验相当。

要点

  • 83侧Artia™辅助假体乳房再造总体并发症率10.8%,无伤口裂开或红乳综合征。
  • 血清肿需抽吸6侧(7.2%),血肿1侧(1.2%),假体丧失2侧(2.4%)。
  • 作者经验中500侧ADM辅助假体再造假体丧失率为4.9%,本研究结果与之相当。

核心结论

  • Artia™辅助假体乳房再造与低且可接受的早期并发症率相关,结果与成熟ADM经验相当。

主要发现

  • 83侧再造中62%为风险降低性乳房切除术后,28%为治疗性乳房切除术后,10%为修整手术。
  • 平均随访276天,总体并发症率10.8%。
  • 血清肿需抽吸6侧(7.2%),血肿1侧(1.2%),假体丧失2侧(2.4%)发生于同一例新辅助化疗后患者。
  • 无伤口裂开或红斑/红乳综合征病例。

关键数值与推荐

  • 总体并发症率10.8%,血清肿需抽吸7.2%,血肿1.2%,假体丧失2.4%。
  • 作者经验中500侧ADM辅助假体再造的假体丧失率为4.9%。

临床怎么用

  • Artia™可作为假体乳房再造的ADM选择之一,早期并发症率与成熟ADM经验相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2015, Artia™ (LifeCell, NJ), a new porcine acellular dermal matrix (ADM), was introduced at our unit. As there is lack of clinical studies on its use in breast reconstruction, the purpose of this prospective study was to assess outcome data for patients who underwent Artia™-assisted breast reconstruction. We compared these data with those of other studies of non-human ADMs in widespread use from the literature. METHODS: All consecutive patients who underwent Artia™-assisted breast reconstruction between July 2016 and February 2018 were identified. A prospective database was maintained, including data of patient demographics, type of reconstruction, type of implant, oncological data if applicable, complication rates and adjuvant treatment delays. RESULTS: Fifty-one patients undergoing 83 implant-based breast reconstructions with Artia™ were included in the study. Of the 83 reconstructions, 62% were performed following risk-reducing mastectomy, 28% following therapeutic mastectomy and 10% for revision procedures. After a mean 276-day follow-up period, the overall complication rate was 10.8%, including 6 breasts (7.2%) developing seromas requiring aspiration, 1 breast developing a haematoma (1.2%) and 2 implant losses (2.4%) in a single patient following neo-adjuvant chemotherapy. There were no cases of wound dehiscence or erythema/red breast syndrome. CONCLUSION: This is one of the first studies demonstrating that Artia™-assisted implant-based breast reconstruction is associated with low and acceptable early complication rates. The results are promising and are comparable to our experience using established ADMs, with an implant loss rate of 4.9% across 500 ADM-assisted implant reconstructions.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Fakim B, Highton L, Gandhi A, et al. Implant-based breast reconstruction with Artia™ tissue matrix. J Plast Reconstr Aesthet Surg. 2019. PMID: 31201107. doi:10.1016/j.bjps.2019.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。